Phase III clinical trials should generally be simple affairs. The rule of thumb is that the standard of care should be compared with a promising intervention among reasonably well-defined patients and the proposed outcome should be readily measurable, generalizable, and clinically meaningful. Ideally, the results, if positive, should change practice and be implemented widely. As